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3TATE-OF-THE-ART PAPER1407The Expanding Role of CMR Imaging for Heart Failureheodoros D. Karamitsos, Jane M. Francis, Saul Myerson, Joseph B. Selvanayagam, Stefan Neubauer
n this state-of-the-art paper, Karamitsos and colleagues review the role of cardiovascular
agnetic resonance (CMR) imaging for the management of patients with heart failure. CMR
ffers a comprehensive assessment of heart failure patients and is now the gold standard
maging technique to assess myocardial anatomy, regional and global function, and viability.
urthermore, it can identify and quantify areas of perfusion abnormality and acute tissue
njury in patients with ischemic cardiomyopathy. In those with nonischemic heart failure,
brosis, infiltration, and iron overload can be detected. The high measurement accuracy of
MR makes it an ideal technique for monitoring disease progression and the effects of
reatment.VIEWPOINT AND COMMENTARY IEWPOINT AND COMMENTARYThe Evidence for Recommending Early Statin Treatment for ACS Patients1425yan P. Morrissey, George A. Diamond, Sanjay Kaul
1434avid D. Waters, Ivy Ku
urrent guidelines recommend initiating high-dose statin therapy pre-discharge regardless of
he baseline low-density lipoprotein level in patients with acute coronary syndromes (ACS)
ith a Class I Level of Evidence: A. Morrissey and colleagues review the evidence and argue
hat early initiation of high-dose statin therapy reduces recurrent ischemia and may reduce
evascularization, but does not confer benefit in terms of hard clinical outcomes, such as death
r myocardial infarction. In addition, it may be associated with increased liver- and muscle-
elated adverse outcomes. Waters and Ku respond by defending the current guidelines. They
ounter that, not only are the guidelines based upon sound evidence of benefit on hard
utcomes, but also that clinically important “soft” outcomes are also reduced within the first
0 days.(continued on page A-24)
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cCUTE MI AND ANTIPLATELET THERAPY1438Higher Clopidogrel Loading Dose Superior in STEMI Patientseorge Dangas, Roxana Mehran, Giulio Guagliumi, Adriano Caixeta, Bernhard Witzenbichler, Jiro Aoki,
an Z. Peruga, Bruce R. Brodie, Dariusz Dudek, Ran Kornowski, LeRoy E. Rabbani, Helen Parise,
regg W. Stone, for the HORIZONS-AMI Trial Investigators
angas and colleagues reviewed results from the HORIZONS-AMI (Harmonizing
utcomes With Revascularization and Stents in Acute Myocardial Infarction) trial, which
nrolled ST-segment elevation myocardial infarction (STEMI) patients undergoing primary
ercutaneous coronary intervention to determine if a higher 600-mg loading dose of
lopidogrel is superior to a 300-mg dose. All patients in the trial received clopidogrel prior to
atheterization, but the dose was operator-dependent. Patients who received 600 mg of
lopidogrel had significantly lower 30-day mortality, reinfarction, and stent thrombosis
ithout higher bleeding rates. There was a similar reduction in net adverse cardiac events
egardless of whether patients were randomized to unfractionated heparin or bivalirudin.
hese results suggest that a 600-mg loading dose of clopidogrel is more efficacious than a
00-mg dose for STEMI patients.ditorial Comment: Daniel I. Simon, Sahil A. Parikh, p. 1447EART RHYTHM DISORDERS
1450se of a Novel Set of Multielectrode
Catheters for Ablation of Persistent Atrial Fibrillationhristoph Scharf, Lucas Boersma, Wyn Davies, Prapa Kanagaratnam, Nicholas S. Peters, Vince Paul,
dward Rowland, Andrew Grace, Simon Fynn, Lam Dang, Hakan Oral, Fred Morady
adiofrequency ablation (RFA) of persistent atrial fibrillation (AF) is a lengthy and
hallenging procedure with a risk of thermal injury to structures near the heart. Scharf and
olleagues describe their results with the use of a novel trio of multielectrode, duty-cycled
FA catheters. During a mean total procedure time of 155 min, complete pulmonary vein
solation and complex fractionated atrial electrogram ablation was achieved in all patients. In
0% of patients, redo ablation was necessary within 3 months. There were no device-related
dverse events. At 6 months, there was a 80% reduction in AF in 80% of patients. This
reliminary study demonstrates efficacy comparable to standard techniques with a low
omplication rate and a relatively short procedure time.(continued on page A-26)
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EARDIAC IMAGING1457CMR Registry Reveals Broad Clinical Utilityliver Bruder, Steffen Schneider, Detlef Nothnagel, Thorsten Dill, Vinzenz Hombach,
eanette Schulz-Menger, Eike Nagel, Massimo Lombardi, Albert C. van Rossum, Anja Wagner,
uerg Schwitter, Jochen Senges, Georg V. Sabin, Udo Sechtem, Heiko Mahrholdt
he EuroCMR Registry Pilot Phase collected information from 20 medical centers in
ermany performing cardiovascular magnetic resonance (CMR) imaging to evaluate the
ndications, image quality, safety, and impact on patient management of CMR imaging.
hese results are based on more than 11,000 patients, 88% of whom received a gadolinium-
ased contrast agent. The most frequent indications for CMR were workup of myocarditis/
ardiomyopathies (32%), suspected coronary artery disease/ischemia (31%), and myocardial
iability (15%). Image quality was good or excellent in 90% and inadequate in only 1.8%.
evere complications, those that required inpatient monitoring, occurred in only 5 cases
0.05%), and were all associated with stress testing. In 62% of cases, CMR findings resulted
n a change of patient management, and in 16% of cases the final diagnosis based on CMR
as different from the diagnosis before CMR. These results suggest that CMR as used in
linical practice is safe and has a strong impact on patient management.IOMARKERS1467Utility of BNP as a Screening Test for Cardiovascular Disease in Childrenuk M. Law, Andrew W. Hoyer, Mark D. Reller, Michael Silberbach
his study by Law and colleagues assessed the ability of plasma B-type natriuretic peptide
BNP) levels to diagnose significant cardiovascular disease in the pediatric population.
ubjects were eligible for this study if the treating physician requested an urgent pediatric
ardiology consult to evaluate a patient. A BNP level was obtained but the results were
linded. The consulting cardiologist then determined if the patient had a significant
ardiovascular disease. Neonates up to 7 days of age with a BNP 170 pg/ml had a 91%
hance of having significant cardiovascular disease; for older children, a BNP 41 pg/ml
ndicated a 77% chance. Plasma BNP appears to be a useful test to diagnose significant
tructural or functional cardiovascular disease in children, although optimal cutoff values are
ifferent from those in adults.ditorial Comment: Thenral Socrates, Nisha Arenja, Christian Mueller, p. 1476
